van Dekken H - Search Results

1

Molecular evaluation of ablative therapy of Barrett's oesophagus.

Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Hage M, et al. Among authors: van dekken h. J Pathol. 2005 Jan;205(1):57-64. doi: 10.1002/path.1685. J Pathol. 2005. PMID: 15586364 Clinical Trial.

2

Cure of Barrett's carcinoma by ifosfamide chemotherapy.

Siersema PD, Hage M, van der Gaast A, van Dekken H, Kok TC, Tilanus HW, Kuipers EJ. Siersema PD, et al. Among authors: van dekken h, van der gaast a. Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1261-4. doi: 10.1097/00042737-200211000-00016. Eur J Gastroenterol Hepatol. 2002. PMID: 12439123

3

Genomic analysis of Barrett's esophagus after ablative therapy: persistence of genetic alterations at tumor suppressor loci.

Hage M, Siersema PD, Vissers KJ, Dinjens WN, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Hage M, et al. Among authors: van dekken h. Int J Cancer. 2006 Jan 1;118(1):155-60. doi: 10.1002/ijc.21302. Int J Cancer. 2006. PMID: 16032707

4

Barrett's oesophagus is characterized by a predominantly humoral inflammatory response.

Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, Kleinjan A, Kwekkeboom J, van Vliet AH, Siersema PD. Moons LM, et al. Among authors: van vliet ah, van dekken h. J Pathol. 2005 Nov;207(3):269-76. doi: 10.1002/path.1847. J Pathol. 2005. PMID: 16177953

5

Long-term risk of oesophagitis, Barrett's oesophagus and oesophageal cancer in achalasia patients.

Leeuwenburgh I, Haringsma J, Van Dekken H, Scholten P, Siersema PD, Kuipers EJ. Leeuwenburgh I, et al. Among authors: van dekken h. Scand J Gastroenterol Suppl. 2006;(243):7-10. doi: 10.1080/00365520600664201. Scand J Gastroenterol Suppl. 2006. PMID: 16782616 Review.

6

High-grade dysplasia in Barrett's esophagus is associated with increased expression of calgranulin A and B.

Bax DA, Siersema PD, Haringsma J, Kuipers EJ, Vos AJ, Van Dekken H, Van Vliet AH, Kusters JG. Bax DA, et al. Among authors: van vliet ah, van dekken h. Scand J Gastroenterol. 2007 Aug;42(8):902-10. doi: 10.1080/00365520601138189. Scand J Gastroenterol. 2007. PMID: 17613918

7

Biomarkers for risk stratification of neoplastic progression in Barrett esophagus.

Kerkhof M, Kusters JG, van Dekken H, Kuipers EJ, Siersema PD. Kerkhof M, et al. Among authors: van dekken h. Cell Oncol. 2007;29(6):507-17. doi: 10.1155/2007/814950. Cell Oncol. 2007. PMID: 18032827 Free PMC article. Review.

8

Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus.

Kerkhof M, Steyerberg EW, Kusters JG, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD. Kerkhof M, et al. Among authors: van dekken h, van vuuren aj. Cancer Biomark. 2008;4(1):1-10. doi: 10.3233/cbm-2008-4101. Cancer Biomark. 2008. PMID: 18334729

9

Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.

van Dekken H, Hop WC, Tilanus HW, Haringsma J, van der Valk H, Wink JC, Vissers KJ. van Dekken H, et al. Among authors: van der valk h. Am J Clin Pathol. 2008 Nov;130(5):745-53. doi: 10.1309/AJCPO31THGVEUIDH. Am J Clin Pathol. 2008. PMID: 18854267

10

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ. Sikkema M, et al. Among authors: van dekken h, van strien pm. Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28. Am J Gastroenterol. 2009. PMID: 19638963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

173 results

Search Page

Filters